Net margin is calculated as Net Income divided by its Revenue. argenx SE's Net Income for the
three
months ended in Mar. 2026 was €317 Mil. argenx SE's Revenue for the
three
months ended in Mar. 2026 was €1,123 Mil. Therefore, argenx SE's net margin for the quarter that ended in Mar. 2026 was 28.20%.
The historical rank and industry rank for argenx SE's Net Margin % or its related term are showing as below:
FRA:1AE'
s Net Margin % Range Over the Past 10 Years
Min: -1475.28 Med: -113.69 Max: 38.03
Current: 31.91
FRA:1AE's Net Margin % is ranked better than 91.12% of 946
companies
in the Biotechnology industry
Industry Median: -88.815
vs FRA:1AE: 31.91
argenx SE (FRA:1AE) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
argenx SE Net Margin % Related Terms
argenx SE Net Margin % Historical Data
* Premium members only.
The historical data trend for argenx SE's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1AE vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, argenx SE's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
argenx SE Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, argenx SE's Net Margin % distribution charts can be found below:
* The bar in red indicates where argenx SE's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
argenx SE (FRA:1AE) has a Net Margin % of 28.20% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on argenx SE and its competitors. According to the industry distribution chart, argenx SE ranks #84 out of 946 companies in the Biotechnology industry, placing it in the top 8.9%.
Is argenx SE's Net Margin % too high?
argenx SE's current Net Margin % is 28.20%. Based on the distribution chart, argenx SE ranks #84 out of 946 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, argenx SE has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does argenx SE's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, argenx SE ranks #84 out of 946 companies for Net Margin %. This places argenx SE in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on argenx SE and its competitors. argenx SE's current Net Margin % is 28.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is argenx SE stock overvalued right now?
Based on GuruFocus' analysis, argenx SE (FRA:1AE) is currently considered Significantly Undervalued. The stock's GF Value™ is €1,204.08, compared to a current price of €753.20 — trading 37.4% below its estimated fair value. The current Net Margin % is 28.20%. argenx SE's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For argenx SE (FRA:1AE), the current Net Margin % is 28.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is argenx SE (FRA:1AE) Overvalued in 2026?
Based on GuruFocus' analysis, argenx SE stock appears to be undervalued.
The current stock price of €753.20 is trading 37.4% below its estimated GF Value™ of €1,204.08.
GuruFocus considers argenx SE to be Significantly Undervalued.
Key valuation signals for FRA:1AE:
Net Margin %: 28.20%
GF Value™: €1,204.08 vs. price of €753.20 (37.4% below fair value)
No single metric tells the full story. See the FRA:1AE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
78GF Score
Get the complete analysis for FRA:1AE
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1AE has been successfully added to your 
